Wire · opportunities
FDA Expands Lilly's Jaypirca Approval to First-Line CLL/SLL Treatment
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
The FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for first-line treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletion, based on Phase 3 trial data showing an 80% reduction in risk of disease progression or death compared to chemoimmunotherapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 2 Oct 2026 and 5 Oct 2026.
◆ ◆ The Wire takeaway
Your biotech or medtech venture now faces a new market note: first-line CLL patients without 17p deletion can access Jaypirca, reshaping initial treatment decisions and limiting chemoimmunotherapy's role. Assess if your early-stage drug or service competes at this front line or targets patients shifted out by this update.
◆ Coverage
3 sources · first reported 2 Oct 2026 · latest 5 Oct 2026
◆ Related on Wire
◆ Topics